Zhongbo Xu

Mr. Zhongbo Xu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2024 in Medicine
Verified
Journal Article
Open access
ZXZhongbo Xu
Zhongbo Xu
LLLin Li
Lin Li
This integrated study combines bioinformatics, machine learning, and Mendelian randomization (MR) to discover and validate molecular biomarkers for sepsis diagnosis. Methods include differential expression analysis, weighted gene co-expression network analysis (WGCNA) for identifying sepsis-related modules and hub genes, and functional enrichment analyses to explore the roles of hub genes. Machine learning algorithms identify 3 diagnostic genes - CD177, LDHA, and MCEMP1 - consistently highly expressed in sepsis patients. The nomogram model effectively predicts sepsis risk, supported by receiver operator characteristic (ROC) curves. Correlations between diagnostic genes and immune cell infiltration are observed. MR analysis reveals a positive causal relationship between MCEMP1 and sepsis risk. In conclusion, this study presents potential sepsis diagnostic biomarkers, highlighting the genetic association of MCEMP1 with sepsis for insights into early diagnosis.

1 July 2019 in Medicine
Verified
Journal Article
Open access
ZXZhongbo Xu
Zhongbo Xu
XFXin Feng
Xin Feng
LLLin Li
Lin Li
ZHZiyi Hu
Ziyi Hu
YXYuan Xiao
Yuan Xiao
WLWeimin Liao
Weimin Liao
Background: Chronic cerebral circulation insufficiency (CCCI) is a common clinical cerebrovascular disease, especially among middle-aged and elderly patients, which seriously endangers their quality of life and physical and mental health. At present, Oral traditional Chinese patent medicine (OTCPM) is widely used in the treatment of CCCI in China, but its actual efficacy and safety lack of evidence-based evidence. Therefore, we will screen out the most effective OTCPM through a systematic review and network meta-analysis to provide a reliable theoretical basis for clinical decisions. Methods: We will search electronic databases to collect relevant RCT studies from inception to October 2019. Those electronic databases include PubMed, Cochrane Library, Web of Science, EMBASE, China Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), and Wan-fang database. Only randomized clinical trials (RCTs) concerned any OTCPM treatments for CCCI will be collected. The included studies will no restrictions on language or publication year. There were no publication year or language for the included literature. Risk bias tools will assess the quality of the included literature. A Bayesian NMA will be performed to combine the direct and indirect comparisons of TCPMs interventions. The surface under the cumulative ranking curve (SUCRA) will be drawn to display the hierarchy of each TCPMs treatment. All statistical analyses will be implemented using R v3.5.2. and GeMTC v1.4.3. We will publish this systematic review in academic journals. Since this literature review will not involve directly contacting patients, ethical approval and informed consent are not required. Trial registration number: CRD42019123878.

21 July 2023 in Medicine
Verified
Journal Article
Open access
ZXZhongbo Xu
Zhongbo Xu
LLLin Li Li
Lin Li Li
LLLin Li
Lin Li
Modified bazhen decoction (MBZD) is a classical Chinese medicine formula with potential efficacy in the treatment of chronic cerebral circulation insufficiency (CCCI), and its main components and potential mechanisms are still unclear. The study aimed to investigate the active ingredients and mechanism of action of MBZD in treating CCCI through network pharmacology combined with molecular docking. The chemical composition and targets of 11 Chinese herbs in MBZD were retrieved utilizing the traditional Chinese medicine systems pharmacology database and analysis platform platform, and the targets for CCCI were screened by Genecards, online mendelian inheritance in man, therapeutic target database, and comparative toxicogenomics database databases. The targets were genetically annotated with the Uniprot database. We created a compound-target network employing Cytoscape software and screened the core targets for the treatment of CCCI by CytoNCA clustering analysis; the AutoDock Vina program performed molecular docking study of crucial targets. One thousand one hundred ninety-one active compounds were obtained, 2210 corresponding targets were predicted, 4971 CCCI-related targets were obtained, and 136 intersecting genes were identified between them. The central core targets were IL6, MAPK14, signal transducer and activator of transcription 3, RELA, VEGFA, CCND1, CASP3, AR, FOS, JUN, EGFR, MAPK1, AKT1, MYC, and ESR1; gene ontology functional enrichment analysis yielded 911 gene ontology items ( P < .01), while Kyoto Encyclopedia of Genes and Genomes pathway enrichment yielded 138 signal pathways ( P < .01), primarily including oxidative reactions, vascular regulation, apoptosis, and PI3K-Akt signaling pathway. The molecular docking results showed that the core active component of MBZD had good binding with the main target. This research initially uncovered the mechanism of action of MBZD via multi-component-multi-target-multi-pathway for the treatment of CCCI, providing the theoretical basis for the clinical application of MBZD.

14 October 2022 in Medicine
Verified
Journal Article
Open access
ZXZhongbo Xu
Zhongbo Xu
WYWenyan Yu
Wenyan Yu
LLLin Li Li
Lin Li Li
GWGuojuan Wang
Guojuan Wang
Pancreatic cancer, a common digestive system malignancy, is dubbed the “king of cancers”. The role of pyrophosis-related genes (PRGs) in pancreatic cancer prognosis is yet unknown. In pancreatic cancer and normal tissue, we discovered 9 PRGs that are expressed differently in pancreatic cancer and healthy tissue. Based on the differential expression of PRGs, 2 clusters of pancreatic cancer cases could be identified. The 2 groups had significant disparities in total survival time. The prognostic model of a 5-PRGs signature was created using least absolute shrinkage and selection operator (LASSO) method. The median risk score was used to split pancreatic cancer patients in The Cancer Genome Atlas (TCGA) cohort into 2 groups: low risk and high risk. Patients classified as low-risk had significantly higher survival rates than those classified as high-risk (P < .01). The same results were obtained by validating them against the Gene Expression Omnibus database (P = .030). Cox regression statistical analysis showed that risk score was an independent predictor of overall survival in pancreatic cancer patients. Functional enrichment analysis revealed that apoptosis, cell proliferation, and cell cycle-related biological processes and signaling pathways were enriched. Additionally, the immunological status of the high-risk group worsened. In conclusion, a novel pyroptosis-related gene signature can be used to predict pancreatic cancer patient prognosis.